Research Area
Product Type
United States ( Change Country )
SNS-314 Chemical Structure
Recommended Products
VX-680 (MK-0457, Tozasertib)
VX-680 (MK-0457, Tozasertib) is the inhibitor of Aurora-A,-B,-C kinases with apparent inhibition constant values of 0.6,18,4.6 nM respectively.
MLN8054
MLN8054 is an Aurora inhibitor, Aurora A (IC50 = 0.004 uM) over Aurora B (IC50 = 0.172 uM).
ZM-447439
ZM-447439 is a poten, selective ATP-competitive Aurora B kinase inhibitor with an IC50 of 50 nM, 1 μM and 250 nM for Aurora B, A and C, respectively.
Danusertib (PHA-739358)
Danusertib (PHA-739358) is a pyrrolo-pyrazole and small molecule aurora kinases and Bcr-Abl kinase inhibitor for aurora A, B, and C with IC50 of 13 nM, 79 nM, and 61 nM, respectively.
MLN8237 (Alisertib)
MLN8237 (Alisertib) is a selective Aurora kinase A inhibitor with a median IC50 of 61 nM.
AT9283
AT9283 is a small molecule a multi-targeted c-ABL, JAK2, Aurora A and B inhibitor with IC50 of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.
AZD1152-HQPA (Barasertib)
AZD1152-HQPA (Barasertib) is a highly potent and selective inhibitor of Aurora B (Ki, 0.36 nM)
CYC116
CYC116 is an Aurora kinase/VEGFR2 inhibitor
ENMD-2076
ENMD-2076 is a antiangiogenic and Aurora kinase inhibitor with IC50 of 3, 13, 350, 23, 40, 93 and 120 nM for Flt-3, AurA, AurB, Src, KDR/VEGFR2 and FGFR1.
JNJ-7706621
JNJ-7706621 is a novel, potent, and broad-spectrum inhibitor of CDK and Aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B with IC50 of 9 nM, 4 nM, 3 nM and 11 nM, respectively.
Biological Activity
| Information | SNS-314 Mesylate is a potent and selective Aurora kinase inhibitor with IC50 of 9, 31, and 3.4 nM for Aurora kinases A, B, and C, respectively. | |||||
|---|---|---|---|---|---|---|
| Targets | Aurora kinase A | Aurora kinase B | Aurora kinase C | |||
| IC50 | 9 nM | 31 nM | 3.4 nM [1] | |||
| In vitro | In HCT116 colorectal carcinoma cell line, with intact or depleted p53 protein levels, SNS-314 Mesylate shows enhanced efficacy when administered sequentially with other standard chemotherapeutic agents and the most profound synergies are identified for agents that activate the spindle assembly checkpoint, e.g., docetaxel and vincristine. [2] A recent study shows that SNS-314 Mesylate shows potent antiproliferative activity in HCT116 cells and inhibits soft agar colony formation. [3] | |||||
| In vivo | The sequential treatment with SNS-314 Mesylate followed by docetaxel 24 hours later produces a significant 72.5% tumor growth inhibition of HCT116 xenografts, while docetaxel and SNS-314 Mesylate as single agents produce no significant inhibition of HCT116 tumor growth. [2] In the HCT116 human colon cancer xenograft model, administration of 50 and 100 mg/kg SNS-314 Mesylate results a dose-dependent inhibition of histone H3 phosphorylation, indicating effective Aurora-B inhibition in vivo. In addition, HCT116 tumors from animals treated with SNS-314 Mesylate exhibits potent and sustained responses including reduction of phosphorylated histone H3 levels, increased caspase-3 and appearance of increased nuclear size. [3] | |||||
| Clinical Trials | SNS-314 Mesylate is currently in Phase I clinical trials in patients with advanced solid tumors | |||||
| Features | ||||||
Protocol
Kinase Assay: [1]
| Aurora-A Kinase Assay | Humanized mouse Aurora A (amino acids 107-403) is expressed in E. coli as described previously. For IC50 assays, compounds are titrated three-fold in DMSO and diluted 12.5-fold into assay buffer (10 mM Tris HCl pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.01% Tween-20, and 0.1% BSA). Compounds are then diluted 4-fold into assay buffer containing Aurora A and FAM-PKAtide at final concentrations of 2 nM and 50 nM, respectively. The kinase reaction is initiated by adding ATP in assay buffer at a final concentration of 10 mM and incubated at 21 °C for 25 minutes. As a positive control, DMSO is added instead of compound and as a negative control assay buffer is added instead of Aurora A. Both control reactions are conducted in triplicate. To detect phosphorylated PKAtide, the kinase reaction is combined with Progressive Binding Solution (1:400 Progressive Binding Reagent, 1× Buffer A, Molecular Devices) in a 1:3 ratio. The mixture is incubated for 30 minutes at 21 °C and the plate was scanned on an Analyst AD with excitation at 485 nm and emission at 530 nm. The percent relative enzymatic activity is calculated by normalizing the mP value for each well to the average positive control. Relative enzymatic activity values are plotted as a function of the logarithm of compound concentration and IC50 values are generated in GraphPad Prism software using a sigmoidal dose-response curve-fit. IC50’s are calculated as the concentration of compound at which enzymatic activity is 50%. |
|---|
Cell Assay: [2]
| Cell lines: | HCT116 SCR and HCT116 p53 RNAi cells |
|---|---|
| Concentrations: | ≤125 nM |
| Incubation Time: | 48 hours |
| Method: | Viability is measured using the CellTiter-Blue cell viability assay. Cells are treated as described above, although with a 5-day incubation period. Cytotoxicity is determined by measuring intracellular ATP using the CellTiter-Glo Luminescence Cell Viability Assay. Cells are seeded in white 96-well tissue culture plates at a density of 1.5-2 × 103 cells/well, and a serial dilution of SNS-314 is dosed in combination with fixed concentrations of either docetaxel or vincristine for a total of 72 hours. Viability is determined as the ratio between the ATP in treated cells versus control cells. Apoptosis is measured using the caspase-Glo 3/7 system. Cells are plated in white 96-well plates as described above and treated first with SNS-314 for 24 hours, washed with 200 μL of 1× PBS, and fresh medium is added with the second agent for 24 hours. |
Animal Study:[2]
| Animal Models: | HCT116 cells are injected s.c. into the right flank of nu/nu mice. |
|---|---|
| Formulation: | SNS-314 is formulated in 20% Captisol R. |
| Dosages: | ≤42.5 mg/kg |
| Administration: | Administered by i.p. |
Chemical Information
| Molecular Weight (WM): | 527.04 |
|---|---|
| Formula: | C18H15ClN6OS2.CH4O3S |
| CAS No.: | 1146618-41-8 |
| Synonyms: |
N/A
|
| Dissolve in (25°C): | DMSO ≥105mg/mL |
| Water ≥6mg/mL | |
| Ethanol <1mg/mL | |
| Storage: | 2 years-20°CPowder |
| 1 week-4°Cin DMSO | |
| 1 month-80°in DMSO |
Quality Control & MSDS
Research Area
Related Inhibitors
Recommended Screening Libraries
Chemical Library
A collection of 864 bioactive compounds
Inhibitor Library
A collection of 481 inhibitors
Kinase Inhibitor Library
A collection of 194 kinase inhibitors
Tyrosine Kinase Inhibitor Library
A collection of 85 tyrosine kinase inhibitors.
FDA Approved Drug Library
A collection of 426 FDA approved drugs
Natural Product Library
A collection of 139 natural products
Chemotherapeutic Agent Library
A collection of 40 chemotherapeutic agents
Epigenetics Compound library
A unique collection of 17 small molecule modulators
Stem Cell Compound library
A unique collection of 47 small molecule inhibitors
GPCR Compound library
A unique collection of 63 GPCR small molecules
We have 1 customer reviews of SNS-314.
- (0)
- (1)
- (0)
- (0)
- (0)
- (0)
- (0)
- (0)
- (0)
Average Customer Review
(1 customer reviews)
-
Click to enlarge
Western blot analysis of Histone H3 and Aurora. 0-10μM SNS-314 was added.
Western blot analysis of Histone H3 and Aurora. 0-10μM SNS-314 was added.
Data independently produced by Dr. Zhang of Tianjin Medical University SNS-314 purchased from Selleck
Check our customer reviews
Western blot analysis of Histone H3 and Aurora. 0-10μM SNS-314 was added.
|
Data independently produced by Dr. Zhang of Tianjin Medical University
We give free samples and rewards to people who would like to provide us useful scientific data(western blot, etc.) > See Details
Recently Viewed Items
Keywords:buy SNS-314 | SNS-314 supplier | purchase SNS-314 | SNS-314 cost | SNS-314 manufacturer | order SNS-314 | SNS-314 distributor